 |
answer text |
<p>The Advance Market Commitment (AMC) for Pneumococcal Vaccines is a dynamic financing
instrument of Gavi, the Vaccine Alliance. Its objective is to reduce deaths from severe
pneumonia by reducing the cost of the pneumococcal vaccine. The AMC does this by incentivising
vaccine manufacturers and generating greater competition by encouraging additional
manufacturers to the market. So far, 114 million children have been vaccinated with
AMC-supported pneumococcal vaccines, saving 762,000 lives.</p><p> </p><p>The expected
total funding for DFID’s contribution to AMC is $485 million from 2010 until the programme
completes in 2020. To date, the UK have made no new financial commitments for AMC
beyond completion of the programme in 2020. As part of the planning process for the
next phase for Gavi, the UK and other stakeholders are exploring all innovative financing
options which can improve global immunisation in poor countries.</p>
|
 |
